High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
Open accessPublished version of a preprint
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: The elderly are highly vulnerable to severe COVID-19. Waning immunity and emergence of Omicron have caused concerns about reduced effectiveness of COVID-19 vaccines. The objective was to estimate vaccine effectiveness (VE) against severe COVID-19 among the elderly. Methods: This nationwide, register-based cohort analysis included all residents aged 70 years and over in Finland. The follow-up started on December 27, 2020, and ended on March 31, 2022. The outcomes of interest were COVID-19-related hospitalization and intensive care unit (ICU) admission timely associated with SARS-CoV-2 infection. VE was estimated as one minus the hazard ratio comparing the vaccinated and unvaccinated and taking into account time since vaccination. Omicron-specific VE was evaluated as the effectiveness observed since January 1, 2022. Results: The cohort included 896,220 individuals. Comirnaty (BioNTech/Pfizer) VE against COVID-19-related hospitalization was 93% (95% CI 89–95%) and 85% (95% CI 82–87%) 14–90 and 91–180 days after the second dose; VE increased to 95% (95% CI 94–96%) 14–60 days after the third dose. VE of other homologous and heterologous three dose series was similar. Protection against severe COVID-19 requiring ICU treatment was even better. Since January 1, 2022, Comirnaty VE was 98% (95% CI 92–99%) and 92% (95% CI 87–95%) 14–90 and 91–180 days after the second and 98% (95% CI 95–99%) 14–60 days after the third dose. Conclusions: VE against severe COVID-19 is high among the elderly. It waned slightly after two doses, but a third restored the protection. VE against severe COVID-19 remained high even after the emergence of Omicron.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640
Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02183-8 · Cited by 1,167
Waning Immunity after the BNT162b2 Vaccine in Israel
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034
Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & Balicer, R. D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02249-2 · Cited by 860 · cited 1×
“However, only a few studies have investigated how well the third dose boosts the VE against severe disease among the elderly [17,19,20].”
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807 · cited 11×
“The present study is concordant with other studies that were conducted prior to the emergence of Omicron and found limited waning of VE against COVID-19-related hospitalization during the first 6 months after the second dose in the elderly [4, 7, 13, 14, 29].”
InfluentialEfficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., & Gray, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119270 · Cited by 600 · cited 1×
“Recent studies of adult populations have estimated the VE against severe Covid-19 caused by Omicron at 50–90% after the second dose [16,21,24,25,30] and at approximately 90% after the third dose [16,21,25,30].”
Research works printed but not linked: 17
- Baum U, Poukka E, Palmu AA, Salo H, Lehtonen TO, Leino T. Effectiveness of vaccination against SARS-CoV-2 infection and COVID-19 hospitalisation among Finnish elderly and chronically ill—an interim analysis of a nationwide cohort study. PLoS ONE. 2021;16(11): e0258704. · DOI
- THL recommends offering a third coronavirus vaccine dose to those over 60 and for medical high-risk groups—Press release—THL. Finnish Institute for Health and Welfare (THL), Finland. https://thl.fi/en/web/thlfi-en/-/thl-recommends-offering-a-third-coronavirus-vaccine-dose-to-those-over-60-and-for-medical-high-risk-groups. Accessed 16 Dec 2021.
- Poukka E, Baum U, Palmu AA, Lehtonen TO, Salo H, Nohynek H, et al. Cohort study of COVID-19 vaccine effectiveness among healthcare workers in Finland, December 2020–October 2021. Vaccine. 2022;40(5):701–5. · DOI · Paper page
- Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic COVID-19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Europe. 2021;11: 100249. · DOI · Paper page
- Berec L, Šmíd M, Přibylová L, Májek O, Pavlík T, Jarkovský J, et al. Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. PLoS ONE. 2022;17(7): e0270801. · DOI
- Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of COVID-19 vaccines over a 9-month period in North Carolina. N Engl J Med. 2022;386(10):933–41. · DOI · Paper page
- Machado A, Kislaya I, Rodrigues AP, Sequeira D, Lima J, Cruz C, et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: a cohort study based on data-linkage of national registries February–September 2021. PLoS ONE. 2022;17(9): e0274008. · DOI
- Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against COVID-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421–30. · DOI · Paper page
- Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386(16):1532–46. · doi:10.1056/nejmoa2119451 · Paper page
- Drawz PE, DeSilva M, Bodurtha P, Benitez GV, Murray A, Chamberlain AM, et al. Effectiveness of BNT162b2 and mRNA-1273 second doses and boosters for SARS-CoV-2 infection and SARS-CoV-2 related hospitalizations: a statewide report from the Minnesota Electronic Health Record Consortium. Clin Infect Dis. 2022 Feb 7;ciac110. · doi:10.1101/2021.12.23.21267853
- Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities—surveillance results from southern Sweden, July 2021 to January 2022. Eurosurveillance. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.9.2200121. · DOI
- Salo H, Lehtonen T, Auranen K, Baum U, Leino T. Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: a population-based register study with implications to vaccinations. Vaccine. 2022;40(24):3345–55. · DOI
- Baum U, Kulathinal S, Auranen K. Spotlight influenza: estimation of influenza vaccine effectiveness in elderly people with assessment of residual confounding by negative control outcomes, Finland, 2012/13 to 2019/20. Eurosurveillance. 2021. https://doi.org/10.2807/1560-7917.ES.2021.26.36.2100054. · DOI
- Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. Eurosurveillance. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000153. · DOI
- Lytras T, Kontopidou F, Lambrou A, Tsiodras S. Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign. J Med Virol. 2022;jmv.27934. · DOI
- THL. Expert group on vaccines recommends longer gap between coronavirus vaccinations and giving AstraZeneca vaccine to those under 70—Press release—THL. Finnish Institute for Health and Welfare (THL), Finland. https://thl.fi/en/web/thlfi-en/-/expert-group-on-vaccines-recommends-longer-gap-between-coronavirus-vaccinations-and-giving-astrazeneca-vaccine-to-those-under-70. Accessed 2 Mar 2022.
- Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. Nat Commun. 2021;12(1):7217. · doi:10.1038/s41467-021-27410-5
Cited by
Feikin, D. R., Abu-Raddad, L. J., Andrews, N., Davies, M.-A., Higdon, M. M., Orenstein, W. A., & Patel, M. K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.069 · Cited by 83
Guo, K., Ni, P., Chang, S., Jin, Y., Duan, G., & Zhang, R. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.02.005 · Cited by 12
Metadata
- Authors
- Baum, U., Poukka, E., Leino, T., Kilpi, T., Nohynek, H., & Palmu, A. A.
- Venue
- BMC Infectious Diseases
- Published
- 2022-11-05
- Volume
- 22
- Issue
- 1
- Pages
- 816-816
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W4308496305
- Cited by
- 46
- References
- 18
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. https://app.cochat.ai/papers/10.1186/s12879-022-07814-4
- The paper
- Baum, U., Poukka, E., Leino, T., Kilpi, T., Nohynek, H., & Palmu, A. A. (2022). High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. BMC Infectious Diseases. https://doi.org/10.1186/s12879-022-07814-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.